On Tuesday 11 June, along with a number of business leaders including Deutsche Bank’s Global Head of Branding Communications and CSR, (Agent)Lareena Hilton and Mayor for the West Midlands (Agent) Andy Street CBE and other inspirational agents, Cure Leukaemia announced its nationwide expansion at an exclusive event hosted by KPMG, Birmingham revealing the details of the Put Us Out of Business campaign.
Cure Leukaemia are proud to announce that, thanks to the transformational UK Charities of the Year partnership with Deutsche Bank, from January 2020, the charity will begin funding specialist research nurses across the UK, for a minimum of three years in 12 different centres. The nurses will work with a Hub based in the Centre for Clinical Haematology, Birmingham to deliver the Trials Acceleration Programme (TAP) thereby allowing rapid assessment of new treatments for blood cancers.
12 Centres have now been selected from 21 applications by an International Peer Review Panel
Grants of £50,000 per year will be paid to these institutions by Cure Leukaemia to support the employment of a research nurse
The catchment area for these pioneering trials will be at least 20m people
12 UK centres to receive Cure Leukaemia funding from January 2020:
- Beatson West of Scotland Cancer Centre, Glasgow
- Belfast City Hospital, Belfast
- Churchill Hospital, Oxford
- King’s College Hospital, London
- Nottingham City Hospital, London
- Queen Elizabeth Hospital, Birmingham
- Royal Hallamshire Hospital, Sheffield
- Southampton General Hospital, Southampton
- St James’s University Hospital, Leeds
- The Christie, Manchester
- University College Hospital, London
- University Hospital of Wales, Cardiff
In the UK, a person is diagnosed with blood cancer every 14 minutes. It remains the third biggest cancer killer, yet innovative new treatments and trials have the potential to not only save lives but also ultimately eradicate the disease.
Your mission (should you choose to accept it) is to help Cure Leukaemia find effective treatments for all forms of blood cancer within the next 15 years thereby putting the charity out of business.
End of message.
The #MissionPossible in detail
England football Manager Gareth Southgate, BBC Match of the Day presenter Gary Lineker and Watford goalkeeper Ben Foster have shown their support for Cure Leukaemia after the blood cancer charity announced its plans to expand its network of specialist research nurses across the UK.
They each recorded a video message of support which was shown to guests at the launch event for Cure Leukaemia’s plans at KPMG’s offices in Birmingham on Tuesday 11th June.
Thanks to the transformational UK Charities of the Year partnership with Deutsche Bank, blood cancer charity Cure Leukaemia will begin funding specialist research nurses across the United Kingdom from January 2020.
Specialist research nurses will be funded for a minimum of 3 years in 12 Centres across the UK who will work with a Hub based in the Centre for Clinical Haematology, Birmingham to deliver the Trials Acceleration Programme (TAP) thereby allowing rapid assessment of new treatments for blood cancers.
Building on the successful track record of the TAP programme, patients, from a catchment region of 20 million people, will have access to the wave of new drug and cellular therapies which promise to transform the outcomes for patients with blood cancer.
Cure Leukaemia co-founder Professor Charlie Craddock CBE, who made the announcement at the event hosted by Cure Leukaemia’s regional charity partner KPMG, said:
“We are incredibly grateful to Deutsche Bank for providing Cure Leukaemia with this opportunity to expand our impact into Centres across the UK. Since the TAP was first established in 2011, it has worked effectively within the established framework of NCRI haemato-oncology Clinical Study Groups and Working Parties funding 20 new trials which have together recruited more than 1100 patients. In the process, patients have accessed more than £250 million of new drugs they otherwise would not have had access to.
“Cure Leukaemia can now build on these solid foundations and continue the rapid assessment of the wave of pioneering new treatments to treat this dreadful disease that are not currently available to patients and save lives in the process.”
Professor Peter Hillmen, a consultant haematologist and Chair of the TAP steering committee said:
“This is a critically important piece of the jigsaw to enable us to do innovative trials in the UK and to move towards curing blood cancers. I think that we are on the threshold of cure for many of our diseases and the quicker we get there the better for all patients suffering from blood cancers.”
The event at KPMG Birmingham, which was attended by leading business figures from the Midlands and London including Mayor for the West Midlands Andy Street CBE and Global Head of Brand Communications and CSR, Deutsche Bank, Lareena Hilton who urged business figures to invest in Cure Leukaemia’s vision for the future.
She said: “It is fantastic to see how Deutsche Bank’s UK employees have made a significant positive impact on Cure Leukaemia. The aim of our Charities of the Year programme is to help transform charitable organisations and this is clear evidence of the bank’s impact. At the heart of this global progress are blood cancer patients who will benefit from accessing potentially life saving treatments and all our employees should be proud that their continued efforts are directly helping save lives.”
Professor Craddock also announced a new £1m appeal which would allow Cure Leukaemia to fund new, potentially practice changing clinical trials and clinical staff at the Centre for Clinical Haematology in Birmingham. These new trials and roles would build on Cure Leukaemia’s track record of investment into capital and personnel allowing patients to connect with the wave new drug and transplant therapies which promise to eradicate blood cancer in the future.
Cure Leukaemia Chief Executive James McLaughlin said: “this is a pivotal moment in Cure Leukaemia’s history. Through Deutsche Bank’s impact we are able to support the TAP for the next three years allowing patients to continue to benefit across the UK. We have a huge opportunity during that time to garner the support of the business community to invest in our vision to eradicate this disease.
“Our £1m Appeal is a fantastic opportunity for businesses in the Midlands to help facilitate pioneering, world first clinical trials which would be delivered and benefit patients in the Birmingham region. I look forward to discussions with the business community to find ways in which we can work together to make our vision a reality in the coming years.”